Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

How important are gender differences in pharmacokinetics?

Bernd Meibohm1, Ingrid Beierle, Hartmut Derendorf

  • 1Department of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee, Memphis, Tennessee 38163, USA. bmeibohm@utmem.edu

Clinical Pharmacokinetics
|May 31, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dose optimization of inhaled tigecycline in humans to overcome inherent adverse events and maximize bacterial clearance using a physiologically-based pharmacokinetic modeling approach.

Frontiers in tuberculosis·2026
Same author

Effect of biofilm formation on the antimicrobial activity of tigecycline against <i>Mycobacterium abscessus</i> in the hollow fiber infection model.

Frontiers in microbiology·2026
Same author

Steady-State Pharmacokinetic Properties of TNX-102 SL, a Sublingual Tablet Formulation of Cyclobenzaprine Hydrochloride (HCl), With Daily Dosing in Healthy Volunteers: A Randomized, Open-Label Trial.

Clinical pharmacology in drug development·2026
Same author

Single-Dose Pharmacokinetic Assessment of TNX-102 SL (Cyclobenzaprine HCl Sublingual Tablets): Results From Randomized, Open-Label Studies in Healthy Volunteers.

Clinical pharmacology in drug development·2026
Same author

Immunopathological outcomes are isolate dependent in chronic Mycobacterium avium complex pulmonary disease.

Disease models & mechanisms·2026
Same author

<i>In vitro</i> PK/PD modeling and simulation to accurately assess the antimicrobial activity of tigecycline against <i>Mycobacterium abscessus</i>.

Antimicrobial agents and chemotherapy·2025

Gender influences how drugs are processed (pharmacokinetics) due to molecular and physiological factors. While differences exist for drug metabolism and transport, their clinical impact on drug effectiveness is often subtle and requires further research.

Area of Science:

  • Pharmacology
  • Drug Metabolism
  • Pharmacokinetics

Background:

  • Gender-related differences in pharmacokinetics are crucial for drug therapy effectiveness.
  • These differences stem from molecular (enzymes, transporters) and physiological factors.
  • Understanding these disparities is key to optimizing drug treatment.

Purpose of the Study:

  • To review the molecular and physiological factors contributing to gender-specific pharmacokinetics.
  • To discuss the implications of these differences for drug disposition and clinical outcomes.
  • To highlight areas where gender disparities in pharmacokinetics and pharmacodynamics require further investigation.

Main Methods:

  • Literature review of studies investigating gender differences in drug metabolism and transport.

Related Experiment Videos

  • Analysis of molecular factors including cytochrome P450 (CYP) enzymes and drug transporters.
  • Examination of physiological factors such as body composition, organ size, and gastric motility.

    • Main Results:

    • Men exhibit higher activity for CYP1A2, CYP2E1, P-glycoprotein, and certain glucuronosyltransferases/sulfotransferases.
    • Women may show higher CYP2D6 activity; no major differences for CYP2C19 and CYP3A.
    • Physiological factors like lower body weight and body fat percentage in women contribute to pharmacokinetic variations.
    • Observed pharmacokinetic differences are generally subtle, with unproven clinical relevance for many drugs.

    Conclusions:

    • Gender significantly influences drug pharmacokinetics through both molecular and physiological mechanisms.
    • While pharmacokinetic gender disparities exist, their clinical significance is often minor, except in specific cases.
    • Pronounced gender differences in pharmacodynamics (e.g., QTc prolongation) necessitate further research to understand their impact on pharmacotherapy.